查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495994

全球心臟去顫器市場：2024-2029 年預測

Global Defibrillators Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計心臟去顫器市場在預測期內將以 5.32% 的複合年成長率成長，從 2022 年的 145.79 億美元增至 2029 年的 209.58 億美元。

心臟去顫器是一種向心臟提供電擊以恢復心率的醫療設備。該裝置可防止或糾正可能導致心臟麻痹的不均勻心率。隨著人口老化，心臟病和搭橋手術的盛行率持續增加。例如，根據世界衛生組織（WHO）的數據，2019年，有1,790萬人因心血管疾病死亡，佔全球死亡人數的32%。

此外，根據美國疾病管制與預防中心的數據，2020 年美國有 697,000 人死於心臟病。此外，根據歐盟統計局的數據，2020 年德國進行了 38,900 例心臟繞道手術，是歐盟成員國手術數量的兩倍多。鑑於心臟病死亡人數和搭橋手術數量不斷增加，未來對心臟去顫器的需求和使用預計也會增加，從而導致心臟去顫器。

全球心臟去顫器市場按類型分為自動體外心臟去顫器（AED）、植入式心臟整流去顫器（ICD）和穿戴式式心臟去顫器（WCD）。預計自動體外心臟去顫器在預測期內將出現相對較高的成長率。自動體外心臟去顫器在治療心臟麻痹方面用途極為廣泛，因為它們可以與心肺復甦術結合以增加復甦的機會。

該設備是攜帶式的，可以自動分析心臟麻痹患者的心率。由於自動體外心臟去顫器的高性能以及心臟衰竭患者數量的增加，預計需求將會增加，這似乎將促進同一細分市場的成長以及心臟去顫器市場在預測期內的成長。

市場促進因素：

  • 心臟麻痹率的上升預計將推動心臟去顫器市場的發展。

由於院外心臟麻痹的發生率不斷增加以及體外心臟去顫器提供的舒適性，心臟去顫器市場預計將成長。已開發國家的政府法規鼓勵在公共場所安裝體外心臟去顫器，像 LifeVest 這樣的穿戴式式心臟去顫器現已在某些地區上市。

體外心臟去顫器預計將變得普及，因為它們比植入式心臟去顫器更安全。心臟麻痹是一種危及生命的疾病，通常需要即時進行去心房顫動。心臟麻痹是一種時間敏感事件，需要快速、時間敏感的干涉，因此需要易於使用且精心放置的心臟去顫器。公共去心房顫動計劃旨在在公共場所提供 AED 並增加早期去心房顫動的機會。

在醫療機構中，早期去心房顫動被優先視為心臟麻痹病例管理中生存鏈的一部分。基本生命支持和心肺復甦術培訓等培訓和意識提升工作正在不斷增加，人們對去心房顫動在心臟麻痹期間挽救生命的重要性的認知也在不斷增強。

  • 政府的措施和投資正在導致心臟去顫器市場的需求激增。

心臟去顫器在心臟麻痹的情況下提供維持個人心率所需的緊急援助，這種情況可能發生在任何地方。有鑑於心臟病日益嚴重的威脅，政府當局正在實施各種舉措、計劃和投資來解決這些與健康相關的問題。例如，2022年5月，德里政府在公車站、火車站、市場等公共場所安裝了自動體外心臟去顫器。此外，2021 年 3 月，蘭金政府宣布將投資 70 萬美元在新斯科細亞省的所有公立學校安裝自動體外心臟心臟去顫器。

此外，威爾斯政府於 2022 年 2 月宣布計劃增加公共機構、社區團體和運動場的心臟去顫器供應，以提高院外心臟麻痹患者的生存率，並宣布投資 6.768 億美元。這種有利的投資和改善公共場所使用心臟去顫器的計劃將導致該設備的需求和使用激增，從而在預測期內推動全球市場的成長。

主要進展

  • 2023 年 8 月 - 皇家飛利浦展示了心臟超音波和人工智慧在心臟護理中的整合，以提高臨床可靠性並提高效率。可攜式設備飛利浦超音波緊湊系統 5500 CV 包括人工智慧驅動的自動化工具，用於應變量化並評估心臟的左心室功能。飛利浦心臟超音波技術每年支援超過 2.4 億名患者的診斷和治療。該公司在其心臟超音波產品組合中提供人工智慧驅動的技術，包括完整的心臟 3D 量化和建模、自動 2D 多普勒和長度測量、可重複的 2D 應變量化以及二尖瓣動態分析。
  • 2023 年 5 月 -遠端患者監護和心臟資料管理解決方案領域的領導者 Implicity 公佈了與法國政府健康資料中心合作進行的一項研究結果。這項研究根據心臟植入電子設備 (CIED) 患者的真實資料，比較了不同遠端監測方法之間的 1 年死亡率、每位患者的住院情況以及住院時間。結果表明，根據所使用的遠端監測方法，死亡率存在很大差異。
  • 2023 年 2 月 -Medtronic推出 Aurora EV-ICD(TM) MRI SureScan(TM) 和 Epsila EV(TM) MRI SureScan(TM)去心房顫動。 Aurora EV-ICD 系統提供傳統 ICD 的救生優勢，同時透過在心臟和靜脈外部放置細線來避免風險。該系統正在美國接受臨床實驗，將為植入 Aurora EV-ICD 的患者提供去心房顫動、抗心搏過速起搏和備用心律調節治療。 Aurora EV-ICD 將植入您的左腋下，Epsila EV 導線將植入您的胸骨下方。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球心臟去顫器市場：按類型

  • 介紹
  • 自動體外電擊器(AED)
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 植入式心臟整流去顫器(ICD)
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 心臟去顫器(WCD)
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章心臟去顫器全球市場：依最終用戶分類

  • 介紹
  • 醫院/診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 門診手術中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章心臟去顫器全球市場：按地區

  • 介紹
  • 北美洲
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 按最終用戶
    • 按國家/地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Boston Scientific Corporation
  • Medtronic
  • ZOLL Medical Corporation
  • AbbottAbott
  • Defibtech LLC
  • Koninklijke Philips NV
  • Nihon Kohden Corporation
  • Schiller AG
  • Stryker Corporation
  • Bexen Cardio
簡介目錄
Product Code: KSI061611897

The global defibrillators market is expected to grow at a CAGR of 5.32% over the forecast period to reach US$20.958 billion by 2029 from US$14.579 billion in 2022.

The defibrillator is a medical equipment that is used to send an electrical shock to the heart for the restoration of the heartbeat. The equipment prevents or corrects uneven heartbeat, which could lead to sudden cardiac arrest. The prevalence of heart disease and bypass surgeries are showing a constant rise coupled with the growing old age population. For instance, according to the World Health Organization, in 2019, the number of deaths recorded due to cardiovascular disease stood at 17.9 million, which represented 32% of all global deaths.

Furthermore, according to the Centers for Disease Control and Prevention, in 2020, in the United States, the number of deaths recorded due to heart disease stood at 697,000. Moreover, according to Eurostat, in 2020, 38,900 heart bypass surgeries were conducted in Germany, which was more than double the number of surgeries conducted in any of the EU's member states. Owing to such a high death count due to heart diseases and an increase in bypass surgeries, the demand and usage of defibrillators in such instances are also projected to increase in the future, thereby boosting the global defibrillator market growth during the forecast period.

The global defibrillator market is segmented based on its type into automated external defibrillators (AED), implantable cardioverter defibrillators (ICD), and wearable cardio defibrillators (WCD). The automated external defibrillator is expected to grow at a relatively higher rate during the forecast period. They are highly applicable during the treatment of sudden cardiac arrest, as the combination of the equipment with CPR improves the resuscitation chances.

The equipment is portable and can automatically analyze the heart rate of an individual experiencing cardiac arrest. Owing to its high-performance features coupled with growing cases of heart failure, the demand for automated external defibrillators is projected to increase, thereby improving the segment growth as well as the global defibrillators market growth during the forecast period.

Market Drivers:

  • Rising prevalence of sudden cardiac arrest is expected to drive the defibrillator market.

The defibrillator market is expected to grow due to the increasing prevalence of out-of-hospital cardiac arrests and the comfort offered by external defibrillators. Government regulations in developed nations are driving the installation of external defibrillators in public places, with wearable defibrillators like LifeVest being launched in certain regions.

The safety of external defibrillators compared to implantable ones is projected to increase adoption. Sudden cardiac arrest is a life-threatening condition that requires immediate intervention, often involving defibrillation. The time-critical nature of sudden cardiac arrest necessitates prompt and time-critical intervention, leading to the demand for accessible and strategically placed defibrillators. Public access defibrillation programs aim to make AEDs available in public spaces, increasing the chances of early defibrillation.

Healthcare settings are prioritizing early defibrillation as part of the chain of survival in managing sudden cardiac arrest cases. Increased training and awareness initiatives, such as basic life support and cardiopulmonary resuscitation training, contribute to increased awareness about the importance of defibrillation in saving lives during sudden cardiac arrest events.

  • The favorable government initiatives and investments are creating a surge in the market for defibrillators demand.

Defibrillators provide the urgent assistance required to maintain the heartbeat of an individual during a sudden cardiac arrest situation, which can occur anywhere. Realizing the growing threat of heart disease, various initiatives, schemes, and investments have been implemented by the governing authorities to tackle such health-related issues. For instance, in May 2022, the Delhi government announced its plans to install automated external defibrillators in public places such as bus stops, railway stations, and marketplaces to provide quick medical assistance to people who suffer cardiac arrest in public places. Additionally, in March 2021, the Rankin government announced investments of US$700,000 to install automated external defibrillators in all public schools in Nova Scotia.

Furthermore, in February 2022, the Welsh government announced investments of US$676.8 million to increase the availability of defibrillators in public organizations, community groups, and sports grounds to improve the survival rate of people who suffer sudden cardiac arrest outside the hospitals. Such favorable investments and plans to increase access to defibrillators in public places will create a surge in the demand and usage of the equipment, thereby boosting their market growth at a global level during the forecast period.

Key Developments:

  • August 2023- Royal Philips as showcased its integration of AI in cardiac ultrasound and cardiac care to improve clinical confidence and increase efficiency. The Philips Ultrasound Compact System 5500 CV, a portable device, includes an AI-powered automation tool for strain quantification, assessing the heart's left ventricle function. Philips' cardiac ultrasound technology supports the diagnosis and treatment of over 240 million patients annually. The company is a leader in integrating AI-powered technology across its cardiac ultrasound portfolio, including full 3D quantification and modeling of the heart, automated 2D Doppler and length measurements, reproducible 2D strain quantification, and dynamic analysis of the mitral valve.
  • May 2023- Implicity, a leader in remote patient monitoring and cardiac data management solutions, revealed the results of a study conducted in collaboration with the French government's Health Data Hub. The study compared mortality rates, hospitalizations per patient, and hospital stays in a year based on real-world data from patients with cardiac implantable electronic devices (CIEDs) to various remote monitoring methods. Results showed significant disparities in mortality rates based on the method of remote monitoring used. Implicity's universal, alert-based remote monitoring platform was associated with better performance compared to historical manufacturers' solutions.
  • February 2023- Medtronic received CE Mark for the Aurora EV-ICD(TM) MRI SureScan(TM) and Epsila EV(TM) MRI SureScan(TM) defibrillation lead, designed to treat fast heart rhythms that can lead to sudden cardiac arrest. The Aurora EV-ICD system offers the life-saving benefits of traditional ICDs while avoiding risks due to its thin wire placement outside the heart and veins. The system is investigational in the United States and offers defibrillation, anti-tachycardia pacing, and backup pacing therapies for patients implanted with the Aurora EV-ICD. The Aurora EV-ICD is implanted below the left armpit, and the Epsila EV lead is placed under the breastbone.

Segmentation:

By Type

  • Automated External Defibrillator (AED)
  • Implantable Cardioverter-Defibrillator (ICD)
  • Wearable Cardio Defibrillator (WCD)

By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Center
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • United Arab Emirates
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL DEFIBRILLATORS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Automated External Defibrillator (AED)
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Implantable Cardioverter-Defibrillator (ICD)
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Wearable Cardio Defibrillator (WCD)
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL DEFIBRILLATORS MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals & Clinics
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Ambulatory Surgical Center
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL DEFIBRILLATORS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Type
    • 7.3.2. By End-User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Type
    • 7.4.2. By End-User
    • 7.4.3. By Country
      • 7.4.3.1. Germany
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. France
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. United Kingdom
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Opportunities and Trends
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Type
    • 7.5.2. By End-User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. Israel
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. United Arab Emirates
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
      • 7.5.3.4. Others
        • 7.5.3.4.1. Market Opportunities and Trends
        • 7.5.3.4.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Type
    • 7.6.2. By End-User
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. South Korea
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. India
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Australia
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Indonesia
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Thailand
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Taiwan
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects
      • 7.6.3.9. Others
        • 7.6.3.9.1. Market Opportunities and Trends
        • 7.6.3.9.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Boston Scientific Corporation
  • 9.2. Medtronic
  • 9.3. ZOLL Medical Corporation
  • 9.4. AbbottAbott
  • 9.5. Defibtech LLC
  • 9.6. Koninklijke Philips N.V
  • 9.7. Nihon Kohden Corporation
  • 9.8. Schiller AG
  • 9.9. Stryker Corporation
  • 9.10. Bexen Cardio